Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Notes Payables (2017 - 2024)

NovaBay Pharmaceuticals (NBY) has disclosed Notes Payables for 5 consecutive years, with $500000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Notes Payables changed N/A to $500000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $500000.0, a N/A change, with the full-year FY2024 number at $500000.0, changed N/A from a year prior.
  • Notes Payables was $500000.0 for Q4 2024 at NovaBay Pharmaceuticals, up from $104000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.2 million in Q1 2020 to a low of $104000.0 in Q2 2020.